China SXT Pharmaceuticals (NASDAQ:SXTC) Issues Quarterly Earnings Results

China SXT Pharmaceuticals (NASDAQ:SXTC) issued its quarterly earnings results on Wednesday. The company reported ($0.07) EPS for the quarter, reports. The firm had revenue of $0.26 million for the quarter.

China SXT Pharmaceuticals Price Performance

SXTC stock opened at $2.45 on Friday. The company’s 50-day moving average is $1.92 and its 200-day moving average is $34.78. China SXT Pharmaceuticals has a 1 year low of $1.25 and a 1 year high of $1,046.98.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC purchased a new position in shares of China SXT Pharmaceuticals in the 3rd quarter worth approximately $78,000. XTX Topco Ltd bought a new position in China SXT Pharmaceuticals in the 4th quarter worth about $36,000. Finally, Virtu Financial LLC increased its stake in China SXT Pharmaceuticals by 107.5% in the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after acquiring an additional 15,013 shares during the last quarter. Hedge funds and other institutional investors own 5.02% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Thursday, June 25th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.